Skip to content

Sample verdict

A real verdict. This one came back as a no.

One run as it was recorded on 21 October 2026, with every source linked. It ends in a no, because that is what the evidence said. Finding out from one run beats finding out after a month of building.

Updated 26 October 2026

1.0 The idea

What was tested

The run began from an idea in the daily sparks feed, Offline Drug Deck: a local-first web app that holds a full drug formulary on the device, searchable on wards and in clinics with no subscription and no connection.

The buyer
Prescribers and clinical staff who look up medications at the point of care.
The claim
Those buyers would pay once for an offline formulary instead of paying a subscription or putting up with ads.

2.0 Buyer evidence

What the buyers said

The only buyer voice the research found. It is paraphrased, and the author is not shown.

The app moved to a subscription in the past year. The better move is to switch to a competitor that offers the same for free.

Paraphrased. A clinician, in a review on the store page of one of the best known apps. The listing

It is a complaint about price, and the fix it names is a free product. It does not ask for something new to be built.

3.0 The market

Who already sells it, and at what price

Each row links to the page the market check read. Prices are what those pages said on the day, and several come from roundups and library guides rather than the vendors.

ProductWhat it isPrice as read
EpocratesFree drug reference with offline access, interaction checker and pill identifier; a paid tier above itPaid tier $174.99 a year, per a 2026 roundup
Epocrates PlusThe paid tier: adds disease information, ICD-10 and CPT codes and infectious disease treatment$174.99 a year, per a university library guide
Micromedex Drug ReferenceDosage, adverse effects and interactions, usable with no connectionFree app; institutions pay for wider access
MedscapePoint-of-care reference with interactions, calculators, pill identifier and a downloadable offline drug databaseFree
UpToDate LexidrugPaid drug reference app that clinicians cite as what they use instead of EpocratesNot stated on the page read
mobilePDRCurrent prescribing information from the PDR for healthcare professionalsFree
iatroXClinical reference tool for pharmacists and prescribersListed among free tools in a 2026 comparison
Nurse's Drug HandbookA drug handbook app for nurses, sold onceDescribed as affordably priced; no figure on the page read
Drugs Dictionary OfflineAndroid drug dictionary with uses, dosage, side effects and precautions; works offlineFree listing
MDCalcClinical calculators and decision supportFree
eMC (electronic Medicines Compendium)Current drug information for the UK marketFree
UpToDateSubscription clinical reference covering drugs and diseasesNot stated on the page read
Lexi-Drugs (Lexicomp)Drug reference app, downloadable for offline use; students get it through institutional subscriptionsNot stated on the page read

Thirteen products, eight of them free and four of those with offline access stated on the pages read. The one product described as a one-time purchase is already on the market.

4.0 Ways to win

Four ways to win, tested

Every candidate is asked whether it could be cheaper, better, narrower, or fix something nobody fixed. Each answer is graded by the evidence found.

CheaperNone

Sell a one-time-purchase offline drug reference below the paid tier of the best known app.

The one buyer with a complaint about spending said the fix was to switch to a free app, not to find a cheaper paid one. Several free apps already work offline, so there is no price below which this is the cheapest option.

BetterNone

Beat the existing apps at looking up a drug at the bedside.

No buyer in the evidence says an existing app does the lookup badly. Every complaint is about the subscription, so there is no stated weakness to be better at.

NarrowerWeak

Serve wards and rural clinics with poor signal using a fully offline formulary.

The offline framing comes from the idea, not from any buyer. The buyers quoted are solving the problem by switching to free apps.

UnfixedWeak

One-time purchase, offline updates and no ads in one product.

A one-time-purchase drug handbook already exists and several free apps work offline, so the combination is a repackaging of things buyers did not ask for.

5.0 The ruling

Filled. Confidence high.

The market is already served: free apps give these buyers offline drug references, and a one-time-purchase handbook exists. The one buyer quoted is switching to a free app, not looking to pay anyone. Read as a verdict, that is a stop for this idea as pitched.

The run cost a short wait instead of weeks of building, and the sources above are yours to check.

What you could do next

Drop it
This is what the evidence supports.
Ask a narrower question
A single specialty, or a country the listed apps do not cover, as a new check. Look for buyers who ask for it in their own words.
Move on
A hunt from anywhere starts from complaints people already wrote.

How a verdict is reached, and where it can go wrong, is on how it works.

Questions

Is this a real run?

Yes. It is one hunt recorded on 21 October 2026, read back from the product as it was stored. The products, prices and links are what that run found. The buyer quote is paraphrased and the author is not shown.

Does this mean offline drug references are a bad idea?

No. It says this idea, as pitched, has no buyer evidence behind it and a crowded set of free alternatives. A different angle, such as one specialty or one country, would be a new check.

Are the prices verified?

They are what the pages the agent read stated on that day, and several come from roundups and library guides rather than the vendors. Treat them as leads to check, not as a price list.

Bring the idea you can’t stop thinking about.

200 free credits. No card.